Market Research Report
FISH Probe Market Size, Share & Trends Analysis Report By Technology (Q FISH, FLOW FISH), By Type (DNA, RNA), By Application (Cancer Research, Genetic Diseases), By End Use, And Segment Forecasts, 2019 - 2026
|Published by||Grand View Research, Inc.||Product code||906546|
|Published||Content info||100 Pages
Delivery time: 2-3 business days
|FISH Probe Market Size, Share & Trends Analysis Report By Technology (Q FISH, FLOW FISH), By Type (DNA, RNA), By Application (Cancer Research, Genetic Diseases), By End Use, And Segment Forecasts, 2019 - 2026|
|Published: June 11, 2019||Content info: 100 Pages||
The global fluorescent in situ hybridization (fish) probe market size is expected to reach USD 1.04 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 6.8% during the forecast period. Increasing global population prone to target diseases and demand for accurate and effective diagnostics of these diseases are the factors attributed to the growth. Increasing use of FISH probes in vitro diagnosis of various infectious diseases is expected to create growth opportunities in near future.
In addition, supportive government initiatives, rising healthcare expenditure and awareness pertaining to the benefits associated with FISH probe technique are expected to drive the market growth during forecast period. Furthermore, technological advancement in Chromogenic In Situ Hybridization (CISH) such as higher storage time for analyzed samples for long duration studies is expected to fuel the demand.
FISH is most commonly used for the detection of genetic diseases such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down's syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia, and cri-du-chat. The genetic disease segment led the overall market in 2018. The probe does not require live cells and can quantify automatically as compared to the conventional cytogenetics, and is more convenient and effective. This factor is anticipated to propel the segment growth. According to a publication from the Centers for Disease Control and Prevention (CDC) in 2018, Down's syndrome was the most common genetic disorders with almost one in every 700 new newborns affected by the disorder.